regulatory status raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-23 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Elexacaftor/tezacaftor/ivacaftor, sold under the brand names Trikafta and Kaftrio, is a fixed-dose combination medication used to treat cystic fibrosis. Elexacaftor/tezacaftor/ivacaftor is composed of a combination of ivacaftor, a chloride channel opener, and elexacaftor and tezacaftor, CFTR modulators. The combination is approved for medical use in the United States for people aged two years of age and older who have cystic fibrosis with a F508del mutation or other mutations in the CFTR gene. It is also approved for use in Canada, the European Union, and Australia. The combination is on the World Health Organization's List of Essential Medicines.
Legio XIV Gemina Martia Victrix (Twin martial and victorious): 57 BC – 48 BC: Julius Caesar, destroyed and reconstituted in 53 BC. Reconstituted by Octavian after 41 BC. Legio XV Apollinaris (Apollo's) 41 BC – 40 BC, Octavian, raised to end the occupation of Sicily by Sextus Pompeius. Legio XVI Gallica (Gallic) 41 BC – 40 BC, Octavian, disbanded after Batavian revolt in AD 70. Legio XVII raised by Octavian in 41 BC, destroyed in Teutoburg forest in AD 9 with XVIII and XIX legions. Legio XVIII raised by Octavian in 41 BC, destroyed in Teutoburg forest in AD 9 with XVII and XIX legions Legio XIX raised by Octavian in 41 BC, destroyed in Teutoburg forest in AD 9 with XVII and XVIII legions Legio XX Valeria Victrix (Victorious Valeria) raised by Octavian in 31 BC. Legio XX Siciliana: 36 BC – 6 BC, Octavian probably for his campaign against Sextus Pompey. Legio XXI Rapax (Predator) raised by Octavian in 31 BC Legio XXV: 49 BC – 42 BC, Julius Caesar Legio XXVI: 49 BC – 30 BC, Julius Caesar legio XXVII: 49 BC – 30 BC, Julius Caesar Legio XXVIII: 47 BC – 31 BC, Julius Caesar Legio XXIX: 49 BC – 30 BC, Julius Caesar Legio XXX Classica (Naval): 48 BC – 41 BC, Julius Caesar
=== Venom spitting === Venom spitting is another venom delivery method that is unique to some Asiatic and African cobras. In venom spitting, a stream of venom is propelled at very high pressures outwards up to 3 meters (300 centimeters). The venom stream is usually aimed at the eyes and face of the target as a deterrent for predators. There are non-spitting cobras that provide useful information on the unique mechanics behind venom spitting. Unlike the elongated oval shaped exit orifices of non-spitting cobras, spitting cobras have circular exit orifice at their fang tips. This combined with the ability to partially retract their fang sheath by displacing the palato-maxillary arch and contracting the adductor mandibulae, allows the spitting cobras to create large pressures within the venom delivery system. While venom spitting is a less common venom delivery system, the venom can still cause the effects if ingested.
Sources: en.wikipedia.org
== Selected articles == Peerschke EI, Zucker MB. Fibrinogen receptor exposure and aggregation of human blood platelets produced by ADP and chilling. Blood. 1981;57:663–70. Peerschke EI, Grant RA, Zucker MB. Decreased association of 45calcium with platelets unable to aggregate due to thrombasthenia or prolonged calcium deprivation. Br J Haematol. 1980;46:247–56. Peerschke EI. Induction of human platelet fibrinogen receptors by epinephrine in the absence of released ADP. Blood. 1982;60:71–7. Peerschke EI. Evidence for interaction between platelet fibrinogen receptors. Blood. 1982;60:973–8. Peerschke EI, Wainer JA. Examination of irreversible platelet-fibrinogen interactions. Am J Physiol. 1985;248:C466–72. Peerschke EI. Decreased accessibility of platelet-bound fibrinogen to antibody and enzyme probes. Blood. 1989;74:682–9. Peerschke EI, Francis CW, Marder VJ. Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. Blood. 1986;67:385–90. Peerschke EI, Galanakis DK. The synthetic RGDS peptide inhibits the binding of fibrinogen lacking intact alpha chain carboxyterminal sequences to human blood platelets. Blood. 1987;69:950–2. Peerschke EI. Bound fibrinogen distribution on stimulated platelets. Examination by confocal scanning laser microscopy. Am J Pathol. 1995;147:678–87. Peerschke EI. Maintenance of GPIIb-IIIa avidity supporting "irreversible" fibrinogen binding is energy-dependent. J Lab Clin Med. 1999;134:398–404. Peerschke EI. Reversible and irreversible binding of fibrinogen to platelets. Platelets. 1997;8:311–7.
== Association football scandals == 1915 British football match-fixing scandal 1964 British football match-fixing scandal Bundesliga scandal (1965) 1971 Bundesliga scandal 1980 Italian football scandal – a match fixing scandal in Italian football involving several major teams. 1986 Totonero 1988 Mexico national football team scandal 1989 Maracanazo of the Chilean team 1993 French football bribery scandal – a match fixing scandal involving a 1992–93 French Division 1 match between Olympique de Marseille and Valenciennes, in which Valenciennes players were bribed by Olympique de Marseille president Bernard Tapie, through Marseille midfielder Jean-Jacques Eydelie. It is believed that Eydelie offered three Valenciennes players (Jorge Burruchaga, Christophe Robert and Jacques Glassman) ₣250,000 to "take the foot off of the gas" in a May 20 match between the sides, so that the team would be fresh to play in the Champions League final soon after. Marseille were subsequently stripped off the 1992–93 French Division 1 title, relegated to Division 2 and handed bans from all 1993 UEFA competitions. The French Football Federation also suspended Eydelie, Robert and Burruchaga, whilst Tapie was replaced as club president by Bernard Moreau. Tapie received a prison sentence of over two years, of which he served six months and received a ₣20,000 fine, whilst Eydelie, Robert, Burruchaga and Marseille general manager Jean-Pierre Bernès were all given prison sentences and fined. Eydelie's prison sentence was a suspended sentence.
=== Systemic antifungal === Ketoconazole has activity against many kinds of fungi that may cause human disease, such as Candida, Histoplasma, Coccidioides, and Blastomyces (although it is not active against Aspergillus), chromomycosis and paracoccidioidomycosis. First made in 1977, ketoconazole was the first orally-active azole antifungal medication. However, ketoconazole has largely been replaced as a first-line systemic antifungal medication by other azole antifungal agents, such as fluconazole and/or itraconazole, because of ketoconazole's greater toxicity, poorer absorption, and more limited spectrum of activity. Ketoconazole is used orally in dosages of 200 to 400 mg per day in the treatment of superficial and deep fungal infections.
== Chemical properties == The oxidized structure of CoQ10 is shown below. The various kinds of coenzyme Q may be distinguished by the number of isoprenoid subunits in their side-chains. The most common coenzyme Q in human mitochondria is CoQ10. Q refers to the quinone head and "10" refers to the number of isoprene repeats in the tail. The molecule below has three isoprenoid units and would be called Q3.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.